Description: Various infections caused by Pefloxacin’s sensitive bacteria: urinary tract infection; respiratory infections; ear、nose and throat infections; gynecology and reproductive system infection; abdomen and liver, bile infections; bone and joint infections ; Skin infections, septicemia and endocarditis; meningitis.

Pharmacological Effects: A pefloxacin for quinolone antibacterial drugs, the mechanism of inhibition of bacterial DNA helix, a broad-spectrum antibacterial activity, Enterobacter bacteria such as E. coli Klebsiella, deformation the genus, genus Shigella, Salmonella spp, typhoid and influenza bacteria, Neisseria, a powerful antibacterial activity against Staphylococcus aureus, and Pseudomonas aeruginosa also have some antibacterial effect. The goods on pneumococcal, and enterococci Streptococcus group only a mild effect. 

Pharmacokinetics: According to information on the goods 0.4 g intravenous drip after the original drug blood concentration of 5.8mg / L, and human plasma protein binding rate is 20 ~ 30%, half bad longer term, about 10 to 13 hours, in the widely distributed in bronchial, lung, liver, kidney, muscle, prostate and other organizations and bile, chest, both in the peritoneal fluid of effective concentration. In addition to a tolerable level of meningeal inflammation in the cerebrospinal fluid, cerebrospinal fluid in plasma concentration is about 60%. The goods mainly in the liver for metabolism, the main product of the N-zone - and to methyl-N-oxide metabolite, N-demethylation of the same Pefloxacin have the same in vitro antibacterial activity. The goods and the major metabolite of renal excretion, or about 58.9% of the dose. 

Indications: Urinary tract infection; Respiratory tract infections; Ear, nose and throat infections; Gynecology, the reproductive system infection; The abdomen and liver, biliary system infection; Bone and joint infections; Skin infection; Sepsis and endocarditis; Meningitis. 

Usage and Consumption: Intravenous drip, common in adult, a 0.4 g, 5% glucose solution 250ml of slow intravenous infusion, once every 12 hours. Patients suffering from jaundice, a daily medication, patients with ascites medication once every 36 hours, suffering from jaundice and ascites patients a medication every 48 hours. Or compliance. 

Adverse reaction: There will be a small number of patients: a gastrointestinal reactions, such as nausea, vomiting, anorexia and diarrhea.  Two photosensitive reaction, nervous system reactions, such as dizziness, vertigo, headache, tremors, insomnia and other.  3 rash, increased serum glutamic - pyruvic transaminase, and reduce the WBC.  Four local injection occasionally symptoms. The response is mild to moderate reaction, disappeared after stopping can be. 

Taboos: This or other quinolones allergies, patients under the age of 18, pregnant women and lactating women and 6 - G6PDH under-Prohibited.